Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of diabetes, obesity, and cardiovascular diseases in the United States. Its products include SYMLIN, an anti hyperglycemic drug used in diabetic patients treated with insulin; and BYETTA, a drug used for the treatment of type 2 diabetes called incretin mimetics. The company also offers Exenatide LAR, a phase II level product for the treatment of type 2 diabetes; AC162352 and Pramlintide (AC137), a phase I and phase II product, respectively, which are used for the treatment of obesity; and AC2592, a product in phase II for the treatment of...